Eikon Therapeutics
3929 Point Eden Way
Hayward
CA
94545
United States
16 articles with Eikon Therapeutics
-
Eikon Therapeutics Announces Long-Term Lease with Alexandria Real Estate Equities, Inc. for New Corporate Headquarters in the San Francisco Bay Area
6/16/2022
Eikon Therapeutics Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, announced the execution of a long-term lease with Alexandria Real Estate Equities, Inc. for its new corporate headquarters.
-
Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors
5/16/2022
Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
-
Eikon Therapeutics Announces the Election of Kenneth C. Frazier to Its Board of Directors
3/31/2022
Eikon Therapeutics Inc. today announced the appointment of Kenneth C. Frazier as an independent director effective April 1, 2022.
-
BioSpace Movers & Shakers, March 25
3/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer
3/23/2022
Eikon Therapeutics, Inc. today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022.
-
Merck has announced the retirement of Dr. Roy D. Baynes, head of global clinical development and chief medical officer of Merck Research Laboratories.
-
Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team
1/6/2022
Eikon is employing super-resolution microscopy and advanced engineering to invent novel medicines that improve and extend life.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.
-
Founded in 2014 and number 3 on BioSpace’s NextGen Bio “Class of 2022” life science startups to watch, Eikon Therapeutics today closed on a Series B financing worth $517.8 million.
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
BioSpace Movers & Shakers, July 2
7/2/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Eikon Therapeutics Appoints Alfred Bowie Jr, PhD as Chief Financial Officer
6/29/2021
Eikon Therapeutics, Inc. today announced that it has named Alfred “Freddie” Bowie, Jr, PhD, to the newly created position of Chief Financial Officer.
-
Eikon Therapeutics Closes $148 Million Series A Financing to Develop High-Throughput, Super-Resolution Microscopy for Drug Discovery
5/5/2021
Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital.
-
Roger Perlmutter, the former president of Merck Research Laboratories, will helm drug discovery startup Eikon Therapeutics, Inc.